My Asymmetric Investment Strategy

The overlooked corner of the market where 100-baggers are born

Most investors avoid microcap healthcare companies like the plague.

Too risky.

Too volatile.

Too many failed trials.

They'd rather chase the latest AI darling or buy another index fund.

But, if I could invest in only one strategy for the rest of my life, it would be finding asymmetric bets in healthcare microcaps.

Not because it's predictable.

But because it's where the biggest mispricings hide in plain sight.

Healthcare microcaps offer the purest form of asymmetric risk-reward in public markets.

When a $50 million biotech discovers a breakthrough treatment, it doesn't become a $60 million company.

It becomes a $5 billion company.

That's the kind of optionality most investors never see.

The Edge Hidden in Plain Sight

Healthcare is different from every other sector.

In software, you're betting on adoption curves and network effects.

In healthcare, you're betting on scientific breakthroughs that can't be disrupted.

When a small company solves a real medical problem with a defensible solution, the market doesn't just reward it – it transforms it.

Think about Moderna pre-COVID. A $6 billion company that most investors ignored.

The mRNA platform wasn't sexy. The financials weren't pretty. The path to profitability was unclear.

But the optionality was enormous.

One pandemic later, Moderna hit a peak market cap of $185 billion.

That's not a fluke.

That's what happens when optionality meets opportunity in healthcare.

Why Most Investors Get This Wrong

The traditional value investing playbook breaks down in healthcare microcaps.

You can't screen for low P/E ratios – most don't have earnings.

You can't demand fortress balance sheets – R&D burns cash.

You can't avoid volatility – binary events move stocks 50%+ overnight.

Instead, you need to think like a venture capitalist with a public market toolkit.

Risk management isn't about avoiding volatility.

It's about controlling position sizes and maximizing optionality.

Small bets.

Huge potential outcomes.

Mathematical expectancy in your favor.

My Framework: Optionality Over Everything

Here's how I think about healthcare microcaps:

💡 Look for Multiple Shots on Goal

• Pipeline diversity across indications

• Platform technologies with broad applications

• Regulatory pathways that create locked-in advantages

💡 Focus on Real Problems, Not Imaginary Markets

• Diseases with genuine unmet medical need

• Clear regulatory pathways to approval

• Willing-to-pay customers (patients, insurers, health systems)

💡 Back Founder-Led Teams with Skin in the Game

• Management owns meaningful equity

• Track record of value creation

• Deep domain expertise, not just MBA credentials

💡 Find Narrative Dislocation

• Market story lags scientific reality

• Temporary setbacks create permanent discounts

• Catalyst-rich environments with binary outcomes

Position Sizing: The Key to Asymmetric Investing

Here's how I structure positions:

• Initial positions: 1-2% – Small enough that total loss doesn't matter

• Conviction adds: Up to 5% – As catalysts approach and data validates thesis

• Home runs: Let them run – When optionality hits, don't cap the upside

The math is simple: Lose 1x on the failures, make 10-100x on the winners.

I only need to be right 10-20% of the time to generate life-changing returns.

What This Newsletter Will Cover

Healthcare microcaps aren't for everyone.

They're volatile.

They're complex.

They require patience and conviction.

But for investors willing to do the work, they offer something increasingly rare in public markets:

Genuine asymmetric opportunities where small amounts of capital can generate life-changing returns.

For every 1,000 microcap healthcare companies, maybe 1 or 2 have legitimate asymmetric potential with the right combination of science, management, and market opportunity.

That's why this newsletter exists.

We release investment theses of 2-3 potential healthcare microcap opportunities each month that meet my criteria:

✅ Asymmetric risk-reward profiles
✅ Multiple shots on goal
✅ Experienced, aligned management
✅ Real problems worth solving
✅ Mispriced optionality

There are simply not enough of these opportunities out there, so we'll only focus on the absolute best candidates we can find.

In addition to this, I'll also break down:

• How to read clinical trial data

• Understanding regulatory pathways

• Spotting narrative dislocations

• Managing binary risk

• Case studies of past winners and losers

As a launch discount, we are offering 25% off our annual plan.

You can get that here if you want:

Thanks for reading,

Nico

---

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of Schwar Capital. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.